TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV:NRX) (OTCQB:NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been selected to present at MIXiii 2025, Israel’s premier Health Tech conference, organized by the Israeli Advanced Technology Industries. NurExone will participate in a special session, Innovation in Ophthalmology, showcasing cutting-edge advancements in vision-related healthcare technology.
At the conference, NurExone will present preclinical results demonstrating significant optic nerve regeneration – a promising treatment pathway for glaucoma and other eye diseases. The presentation will take place during the Pharma Company Presentations session, moderated by Tarsier Pharma, alongside leading biotech companies, which includes: OptiMedRx, Galimedix, Ocuvia, and Everads Therapy. The preclinical study, conducted at Tel Hashomer’s Goldschleger Eye Institute, was led by Prof. Michael Belkin, Dr. Ifat Sher and Prof. Ygal Rotenstreich.
In addition, at MIXiii 2025, Professor Belkin will be honoured as a recipient of the Lifetime Achievement Award in recognition of his pioneering contributions to ophthalmic innovation and medical technology. A key scientific advisory board member and collaborator at NurExone, Professor Belkin is also the inventor of the Belkin Vision technology, which was recently acquired by Alcon in a deal valued at up to $466 million.
NurExone is further advancing its glaucoma research with the launch of a new preclinical study using its lead product, ExoPTEN, on a large group of small animals. This study aims to replicate and expand upon the positive results observed in previously announced preclinical research further exploring ExoPTEN’s potential in neurodegenerative eye disease treatment.
“The potential of ExoPTEN for ophthalmology is truly exciting,” said Professor Belkin. “Advancing this research could open new doors for treating neurodegenerative eye diseases that are currently untreatable, and I’m thrilled to support NurExone in this groundbreaking work.”
“MIXiii is an incredible platform to showcase NurExone’s groundbreaking work in regenerative medicine and our vision for revolutionizing treatment of certain eye diseases,” said Dr. Lior Shaltiel, CEO of NurExone Biologic. “We are also proud to celebrate Professor Belkin’s extraordinary contributions. His lifelong dedication to medical innovation continues to inspire and drive progress in the field. We are honoured to have him as an investor, collaborator, and professional consultant.”
About NurExone
NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV“), OTCQB and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including Orphan Drug Designation, facilitate the roadmap towards clinical trials in …
